Comparative Pharmacology
Head-to-head clinical analysis: ANCEF versus CEFDINIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF versus CEFDINIR.
ANCEF vs CEFDINIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cefdinir is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking, leading to cell lysis and death.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
300 mg orally twice daily for 5-10 days, or 600 mg orally once daily for 10 days.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
Clinical Note
moderateCefdinir + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefdinir."
Clinical Note
moderateIron sucrose + Cefdinir
"The serum concentration of Cefdinir can be decreased when it is combined with Iron sucrose."
Clinical Note
moderateIron + Cefdinir
"The serum concentration of Cefdinir can be decreased when it is combined with Iron."
Clinical Note
moderateFerric pyrophosphate + Cefdinir
Terminal elimination half-life: 1.7 ± 0.6 hours (range 1.4-2.3 h) in healthy adults; prolonged in renal impairment (e.g., up to 8 hours in end-stage renal disease).
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Renal: 90-95% unchanged in urine via glomerular filtration and tubular secretion. Biliary/fecal: <1% biliary, <5% fecal.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The serum concentration of Cefdinir can be decreased when it is combined with Ferric pyrophosphate."